FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 322:281-285 February 1, 1990 Number 5 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Cytotoxic agents have long been used in Behcet's syndrome, especially for eye involvement, but their effectiveness has been uncertain. We conducted a two-year randomized, placebo-controlled, double-blind trial of azathioprine (2.5 mg per kilogram of body weight per day) in Turkish men with Behcet's syndrome without eye disease (group 1; n = 25) or with eye disease (group 2; n = 48). Corticosteroid treatment remained available to all the patients. All six patients withdrawn from the study because of severe eye disease were receiving placebo (P less than 0.001). Azathioprine was superior to placebo in the prevention of new eye disease in group 1 (1 vs. 8 patients; P less than 0.01) and in group 2 among the 14 patients who at entry had disease in only one eye (P less than 0.001). There were fewer episodes of hypopyon uveitis (1 vs. 15; P less than 0.001) among the group 2 patients who took azathioprine. The patients taking azathioprine also had less frequent oral ulcers, genital ulcers, and arthritis. There were no serious side effects attributable to azathioprine. We conclude that azathioprine is effective in controlling the progression of Behcet's syndrome, especially its most serious manifestation, eye disease.

Source Information

Department of Rheumatology, Cerrahpasa Medical Faculty, University of Istanbul, Turkey.

This article has been cited by other articles:

• Hatemi, G, Silman, A, Bang, D, Bodaghi, B, Chamberlain, A M, Gul, A, Houman, M H, Kotter, I, Olivieri, I, Salvarani, C, Sfikakis, P P, Siva, A, Stanford, M R, Stubiger, N, Yurdakul, S, Yazici, H (2008). EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 67: 1656-1662 [Abstract] [Full Text]  
• Niccoli, L., Nannini, C., Benucci, M., Chindamo, D., Cassara, E., Salvarani, C., Cimino, L., Gini, G., Lenzetti, I., Cantini, F. (2007). Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology (Oxford) 46: 1161-1164 [Abstract] [Full Text]  
• Sfikakis, P. P., Markomichelakis, N., Alpsoy, E., Assaad-Khalil, S., Bodaghi, B., Gul, A., Ohno, S., Pipitone, N., Schirmer, M., Stanford, M., Wechsler, B., Zouboulis, C., Kaklamanis, P., Yazici, H. (2007). Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. Rheumatology (Oxford) 46: 736-741 [Full Text]  
• Gutfleisch, M., Spital, G., Mingels, A., Pauleikhoff, D., Lommatzsch, A., Heiligenhaus, A. (2007). Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations. Br. J. Ophthalmol. 91: 345-348 [Abstract] [Full Text]  
• Baker, K B, Spurrier, N J, Watkins, A S, Smith, J R, Rosenbaum, J T (2006). Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. Br. J. Ophthalmol. 90: 1481-1485 [Abstract] [Full Text]  
• Mat, C., Yurdakul, S., Uysal, S., Gogus, F., Ozyazgan, Y., Uysal, O., Fresko, I., Yazici, H. (2006). A double-blind trial of depot corticosteroids in Behcet's syndrome. Rheumatology (Oxford) 45: 348-352 [Abstract] [Full Text]  
• Tarzi, M. D., Lightman, S., Longhurst, H. J. (2005). An exacerbation of Behcet's syndrome presenting with bilateral papillitis. Rheumatology (Oxford) 44: 953-954 [Full Text]  
• Kotter, I, Zierhut, M, Eckstein, A K, Vonthein, R, Ness, T, Gunaydin, I, Grimbacher, B, Blaschke, S, Meyer-Riemann, W, Peter, H H, Stubiger, N (2003). Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br. J. Ophthalmol. 87: 423-431 [Abstract] [Full Text]  
• Sfikakis, P P (2002). Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61: ii51-53 [Abstract] [Full Text]  
• Alpsoy, E., Durusoy, C., Yilmaz, E., Ozgurel, Y., Ermis, O., Yazar, S., Basaran, E. (2002). Interferon Alfa-2a in the Treatment of Behcet Disease: A Randomized Placebo-Controlled and Double-blind Study. Arch Dermatol 138: 467-471 [Abstract] [Full Text]  
• Travis, S P L, Czajkowski, M, McGovern, D P B, Watson, R G P, Bell, A L (2001). Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor {alpha} antibody. Gut 49: 725-728 [Abstract] [Full Text]  
• Sarigul, A., Koramaz, I., Demirturk, O., Boke, E., Sukru Mercan, A. (2000). Pseudoaneurysm Formation in Surgically Treated Behcet's Syndrome: A Case Report. ANGIOLOGY 51: 349-354 [Abstract]  
• Whallett, A.J., Thurairajan, G., Hamburger, J., Palmer, R.G., Murray, P.I. (1999). Behcet's syndrome: a multidisciplinary approach to clinical care. QJM 92: 727-740 [Abstract] [Full Text]  
• Barnes, C. G., Yazici, H. (1999). Behcet's syndrome. Rheumatology (Oxford) 38: 1171-1174 [Full Text]  
• Demiroglu, H., Yalçin, S., Büyükasik, Y., Özcebe, O. I., Dündar, S. (1998). Increased erythrocyte aggregation as an indicator for an aggressive clinical course in Behcet's disease: a prospective study. Ann Rheum Dis 57: 694-696 [Abstract] [Full Text]  
• Kötter, I., Eckstein, A. K, Stübiger, N., Zierhut, M. (1998). Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot study. Br. J. Ophthalmol. 82: 488-494 [Abstract] [Full Text]  
• Dick, A. D, Azim, M., Forrester, J. V (1997). Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Br. J. Ophthalmol. 81: 1107-1112 [Full Text]